New scan could spot Hard-to-Find breast cancer spread
NCT ID NCT07020806
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new radioactive tracer called [68Ga]Ga DOTA-5G for PET/CT scans in 30 people with metastatic lobular breast cancer. The goal is to see if it can find cancer lesions better than current methods and to check its safety. Participants receive one injection and are scanned at 1 and 2 hours after.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- [68Ga]Ga DOTA-5G (a radioactive tracer for PET imaging)
- What this could lead to
- If successful, this could provide a more accurate way to detect metastatic lobular breast cancer, helping doctors plan better treatment.
- What could go wrong
- This is a very early Phase 1 trial with only 30 people. The imaging agent may not prove more effective than current scans, and safety is still being checked.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LOBULAR BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California Davis
RECRUITINGSacramento, California, 95817, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.